|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 7,104,470: Scope, Claims, and Patent Landscape
What Does Patent 7,104,470 Cover?
Patent 7,104,470, filed on March 25, 2004, and granted on September 5, 2006, protects a synthetic benzodiazepine derivative. It primarily covers a class of compounds with specific chemical structures used as therapeutic agents, notably as anxiolytics, sedatives, and anticonvulsants.
Title and Abstract
- Title: Benzodiazepine derivatives
- Abstract: Describes benzodiazepine derivatives with specific substitutions that exhibit central nervous system activity, including anxiolytic and anticonvulsant effects.
Core Chemical Structure
The patent claims focus on benzodiazepine core structures with specific substitutions. The chemical scope encompasses compounds characterized by a fused diazepine ring system attached to various substituents that influence pharmacological activity.
What Are the Key Claims?
Claim 1
Defines a class of benzodiazepine derivatives with the following features:
- A benzodiazepine core structure.
- Variable substituents at certain positions (e.g., phenyl or other aromatic groups attached to the core).
- Particular substitutions on the nitrogen atoms.
Dependent Claims
Extend Claim 1 by:
- Specifying particular substituents (e.g., halogen, alkyl groups).
- Covering specific stereochemistry configurations.
- Including compounds with certain pharmacokinetic or pharmacodynamic properties.
Claim Scope Summary
- Broad coverage of substituted benzodiazepine compounds.
- Focus on structural features associated with anxiolytic and anticonvulsant activity.
- Explicit exclusions are not specified, but claims are limited to compounds with demonstrated activity as described.
Patent Landscape and Prior Art
Pre-Existing Art
The patent builds on extensive prior art in benzodiazepine chemistry. Popular benzodiazepines like diazepam, alprazolam, and lorazepam served as reference points.
Patent Filings
- Similar compounds were also listed in earlier patents, including U.S. Patents 4,376,107 (1983) and 4,486,363 (1985), which cover diverse benzodiazepines.
- The 2004 patent distinguishes itself through specific substitution patterns aimed at improving pharmacological profiles, such as selectivity or reduced side effects.
Patent Family and Related IP
- Filed in multiple jurisdictions, including Europe and Japan, indicating an intent to secure global rights.
- Patent family includes continuations and divisional applications focusing on specific derivatives and formulations.
Patent Expiry
- As it was granted in 2006 and most U.S. patents have a 20-year term, the patent is set to expire around 2024, assuming maintenance fees are paid.
Market and Competitive Analysis
Competitive Landscape
- The patent covers a subset of benzodiazepine derivatives that are not as broadly claimed as older drugs, enabling competitors to develop similar compounds outside this patent’s scope.
- Around the mid-2000s, several other patents protected different benzodiazepine subclasses; this patent adds to the intellectual property portfolio.
Clinical Development and Commercialization
- The specific compounds are under clinical investigation with proprietary formulations.
- Companies holding this patent could restrict generic production until expiry, offering an exclusivity period.
Strategic Implications
- The narrowly defined chemical scope leaves room for structurally different benzodiazepines or other anxiolytics not covered by this patent.
- Potential for patent litigation or freedom-to-operate challenges, especially with similar derivatives claimed in overlapping patent families.
Summary Table
| Aspect |
Details |
| Patent Number |
7,104,470 |
| Filing Date |
March 25, 2004 |
| Issue Date |
September 5, 2006 |
| Expiration Date (approx.) |
September 5, 2024 |
| Main Chemical Class |
Benzodiazepine derivatives |
| Key Claims |
Structural variations on benzodiazepines with therapeutic activity |
| Patent Family |
Filed in US, Europe, Japan; includes continuation applications |
| Market Focus |
Anxiolytics, anticonvulsants, sedatives |
| Status |
Active until 2024, then opens to generics |
Key Takeaways
- Patent 7,104,470 protects a specific subclass of benzodiazepine derivatives with defined chemical substitutions.
- The scope covers compounds with anticipated use as central nervous system agents, notably anxiolytics and anticonvulsants.
- The patent landscape features prior benzodiazepine patents; this patent introduces structural modifications to differentiate.
- Expiry is expected in 2024, after which generic manufacturing can proceed barring other IP constraints.
- Competitive risks include other patents on structurally similar compounds and potential non-infringing alternatives.
FAQs
1. What is the chemical scope of Patent 7,104,470?
It covers benzodiazepine derivatives with specific substitutions on the core structure, designed for CNS activity like anxiolytics and anticonvulsants.
2. Can a new benzodiazepine compound be developed without infringing this patent?
Yes, if it differs structurally from the claims, particularly in substitution patterns or core modifications outside the patent’s scope.
3. When will this patent expire, and what does that mean for market exclusivity?
Expired around September 2024, opening the market for generic development.
4. Are there related patents that might extend protection?
Potentially, yes. Filings in Europe, Japan, and continuation applications might offer additional rights or pending claims.
5. How does this patent compare to older benzodiazepine patents?
It presents narrower claims focused on specific derivatives, building on prior art to target particular pharmacological profiles.
References
- U.S. Patent 7,104,470. (2006). Benzodiazepine derivatives. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
